Analysis on rational application of esomeprazole for injection in hepatobiliary perioperative period
-
摘要: 目的 了解东方肝胆外科医院（简称"我院"）注射用艾司奥美拉唑钠在肝胆外科围术期应用的合理性，为肝胆手术围术期合理用药提供参考。 方法 用回顾性研究方法，通过查阅电子病历、医嘱和检验结果等途径，随机采集了2017年1月至9月300例使用注射用艾司奥美拉唑钠患者的相关信息。300例病例艾司奥美拉唑的使用频次为416次，从给药时间、用药疗程、用法用量、溶剂和应激性溃疡危险因素等方面进行分析。 结果 给药时间的合理率是15.67%（47/300），用药疗程的合理率是10.67%（32/300），用法的合理率是75%（312/416），用量的合理率是100%（416/416），溶媒的合理率为100%（416/416），具有应激性溃疡危险因素的患者占3.33%（10/300）。 结论 我院肝胆外科围术期应用艾司奥美拉唑合理性有待提高，临床药师应加强临床用药教育以提高合理用药水平。Abstract: Objective To investigate the rationality of esomeprazole for injection in hepatobiliary perioperative period of Eastern Hepatobiliary hospital (hereinafter referred to as our hospital), and to provide reference for the rational drug use in hepatobiliary perioperative. Methods By retrospective investigation, information of 300 randomly patients was collected from Jan to Sep in 2017 with esomeprezole for injection through consulting the electronic medical records, doctor's advice, inspection, etc. Of the 300 cases of medical records with esomeprazole for injection, the use frequency of esomeprazole were 416, statistical analysis was conducted in terms of the administration time, treatment course, usage and dosage, solvent, and the risk of stress ulcer. Results The rational rate of the administration time was 15.67%(47/300), the treatment course was 10.67%(32/300),the usage was 75%(312/416),dosage and solvent were 100%(416/416),and the ratio of patients with SU risk factors was 3.33%(10/300). Conclusion The rational application of esomeprezole in our hospital still need to be improved. The clinical pharmacists should strengthen clinical medicine education to improve rational drug use in our hospital.
-
Key words:
- esomeprazole /
- perioperative period /
- clinical indications
-
[1] KUPIEC TC, ALOUMANIS V, BEN M, et al. Physical and chemical stability of esomeprazole sodium solutions[J]. Ann Pharmacother, 2008,42(9):1247-1251. [2] 吕小娟, 艾伟鹏, 马林. 质子泵抑制剂预防危重症患者并发应激性溃疡的循证药物经济学评价[J].中国医院药学杂志,2015,35(24):2237-2240. [3] UCHIYAMA T, HIGURASHI T, KURIYAMA H, et al. Oral esomeprazole vs injectable omeprazole for the prevention of hemorrhage after endoscopic submucosal dissection[J]. World J Gastrointest Endosc, 2017,9(10):514-520. [4] KAGAMI T, YAMADE M, SUZUKI T, et al. Comparative study of effects of vonoprazan and esomeprazole on antiplatelet function of clopidogrel or prasugrel in relation to CYP2C19 genotype[J]. Clin Pharmacol Ther, 2018,103(5):906-913. [5] 黄瑾, 刘正跃, 田泾. 长期大剂量使用质子泵抑制剂的严重不良反应和药学监护[J].中国医院药学杂志,2012,32(20):1648-1651. [6] VIDELA R, SOMMARDAHL CS, ELLIOTT SB, et al. Effects of intravenously administered esomeprazole sodium on gastric juice pH in adult female horses[J]. J Vet Intern Med, 2011,25(3):558-562. [7] 芦小燕, 戴幼琴, 陈维, 等. 基于循证的静脉用质子泵抑制剂预防应激性溃疡的合理性评价标准的建立[J].中国现代应用药学,2015,32(12):1481-1484. [8] 吴明杰. 住院患者注射用质子泵抑制剂不合理应用分析[J].中国医院用药评价与分析,2016,16(02):257-259. [9] MEI J, YU Y, MA J, et al. Evaluation of the effectiveness of esomeprazole treatment strategies in the management of patients with gastroesophageal reflux disease symptoms:a meta-analysis[J]. Pharmazie, 2016,71(5):285-291. [10] ZHOU J, QUINLAN M, GLENN K, et al. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers[J]. Br J Clin Pharmacol, 2016,82(4):1022-1029. [11] 孙敏, 黄坤明, 司继刚. 临床使用质子泵抑制剂的药学监护[J].河北医药,2016,38(02):275-278. [12] 张石革. 质子泵抑制剂临床应用的药学监护[J].中国执业药师,2015,12(07):31-37. -
点击查看大图
计量
- 文章访问数: 3115
- HTML全文浏览量: 579
- PDF下载量: 574
- 被引次数: 0
下载:
